Articles By Jack Cush, MD
October-September 2016 Top Social Media News
Following is a list of top tweets in September and October 2016; they were selected based on the number of clicks, retweets and likes by the viewership. More than 40,000 people were reached with the first one on our list.
Read Article
ACP Guidelines on the Diagnosis and Treatment of Low Back Pain
Low back pain (LBP) is the fifth most common reason for all physician visits in the United States and nearly 25% of all U.S. adults have had LBP in the last 3 months and nearly 6% reported at least 1 episode of severe acute low back pain in the last 1-year.
Read Article
Most Clinicians Do Not Order MRI/CT for Nonspecific Low Back Pain
Low back pain (LBP) is a highly prevalent public health problem. Not surprisingly, imaging of LBP is also an expensive and often overused diagnostic tool.
Read Article
Early Intervention with Corticosteroids and IVIG is Crucial in Kawasaki Disease
The current JAMA Pediatrics issue has published a report showing that adjunctive corticosteroid therapy yielded significantly fewer coronary artery complications compared with intravenous immunoglobulin therapy alone, particularly among high-risk patients with Kawasaki disease.
Read Article
RheumNow Week in Review – 21 October 2016
Dr. Cush Reviews Highlights from the past week on RheumNow.com. Register to receive free daily rheumatology news written by rheumatologists for rheumatologists. Download the podcast at iTunes.com.
Read Article
Prescribing Hope
Everything will be alright in the end; and if it’s not alright, then it’s not yet the end. – Suni Kapoor (from the Best Exotic Marigold Hotel)
Read Article
Good News for Lupus Pregnancies
The Washington Post recently interviewed Dr. Eliza Chakavarty of the OMRF about the evolution in attitudes and outcomes of lupus women who wish to get pregnant.
Read Article
Nor-Switch Study Shows it's Safe to Switch to a Biosimilar
The results of the Nor-Switch study were presented at the United European Gastroenterology annual congress this week demonstrating no significant difference in effect, adverse effects or antibody formation in patients switched from Remicade to the biosimilar infliximab (CT-P13, Remsima).
Read Article
Inflectra Biosimilar Ships in Late November 2016
Pfizer has announced it will ship its new FDA-approved biosimilar, Inflectra, in late November and that it will be priced at a15 percent discount to current wholesale prices.
Read Article
